Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

363
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
363
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

562
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
562
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

386
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
386
Angina IV: Management01:26

Angina IV: Management

376
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
376
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

499
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
499
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of multivessel disease in patients with ST-segment elevation myocardial infarction: questioning routine immediate complete revascularization in all patients.

Coronary artery disease·2026
Same author

Embryo selection using artificial intelligence: moving from validation to responsible clinical integration.

Journal of assisted reproduction and genetics·2026
Same author

Early outcomes of redo-TAVI with the SAPIEN 3 platform: the prospective, multicentre ReTAVI registry.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2026
Same author

(Long-term) efficacy of endotype-based drug therapy on quality of life and symptom management in coronary vasomotion disorders.

International journal of cardiology·2026
Same author

ESC-JCS Joint Symposium at the 89th Japanese Circulation Society Annual Meeting: focus on angina with non-obstructive coronary arteries.

European heart journal·2026
Same author

The future of coronary function testing - angio-derived assessments are on the advance.

International journal of cardiology·2025

Related Experiment Video

Updated: Mar 16, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

6.1K

Pharmacotherapy for coronary microvascular dysfunction.

Peter Ong1, Anastasios Athanasiadis2, Udo Sechtem2

  • 1Department of Cardiology, Robert-Bosch-Krankenhaus, Auerbachstr. 110, Stuttgart 70376, Germany peter.ong@rbk.de.

European Heart Journal. Cardiovascular Pharmacotherapy
|August 18, 2016
PubMed
Summary

Coronary microvascular dysfunction (CMD) causes angina in patients without blockages in major heart arteries. This review explores current drug treatments for this underdiagnosed condition.

Keywords:
Angina pectorisCoronary microvascular dysfunctionPharmacotherapy

More Related Videos

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.9K
Standardized Rat Coronary Ring Preparation and Real-Time Recording of Dynamic Tension Changes Along Vessel Diameter
07:53

Standardized Rat Coronary Ring Preparation and Real-Time Recording of Dynamic Tension Changes Along Vessel Diameter

Published on: June 16, 2022

4.0K

Related Experiment Videos

Last Updated: Mar 16, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

6.1K
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.9K
Standardized Rat Coronary Ring Preparation and Real-Time Recording of Dynamic Tension Changes Along Vessel Diameter
07:53

Standardized Rat Coronary Ring Preparation and Real-Time Recording of Dynamic Tension Changes Along Vessel Diameter

Published on: June 16, 2022

4.0K

Area of Science:

  • Cardiology
  • Vascular Biology
  • Pharmacology

Background:

  • Coronary microvascular dysfunction (CMD) is a cardiac condition affecting small vessels (<500 µm).
  • It causes myocardial ischaemia symptoms, often in patients without obstructive epicardial coronary artery disease.
  • Underlying mechanisms are diverse and not fully understood, leading to underdiagnosis.

Purpose of the Study:

  • To review current pharmacological treatment strategies for CMD.
  • Focus on patients presenting with angina but lacking epicardial coronary artery disease or myocardial disease.

Main Methods:

  • Literature review of pharmacological interventions for CMD.
  • Analysis of current treatment recommendations and emerging concepts.

Main Results:

  • Limited data exists on the effectiveness of pharmacological treatments for CMD.
  • Current ESC guidelines suggest aspirin, statins, beta-blockers, and/or calcium-channel blockers.
  • The review highlights the need for more research into effective CMD therapies.

Conclusions:

  • CMD is an important cause of angina, frequently overlooked.
  • Pharmacological management of CMD remains challenging due to limited evidence.
  • Further research is crucial to establish optimal treatment guidelines for CMD.